NetWorth
LeaderPortfolio
Boehringer
M
Rank #607
GERMANY•Healthcare•Pharmaceuticals

Mathias Boehringer

Net Worth
$6.494B
0% (24h)
Mathias Boehringer, a key figure in the pharmaceutical world, derives his wealth from Boehringer Ingelheim, the largest private pharmaceutical company globally. As of March 2026, his estimated net worth is $6.6 billion. He is part of the Boehringer/Von Baumbach family, who collectively control the company, which was founded in 1885. Boehringer Ingelheim is known for its research and development efforts, with a focus on respiratory diseases, metabolism, immunology, oncology, and central nervous system disorders. Mathias Boehringer, along with other family members, holds an equal share in the company, contributing to its long-standing success.

How to read Mathias Boehringer's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Mathias Boehringer, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $6.494B alongside global rank #607, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (GERMANY) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Mathias Boehringer's early life details are not widely publicized, but his roots are firmly planted in the pharmaceutical legacy of the Boehringer family. The family's history dates back to 1885 when Albert Boehringer founded a small factory in Ingelheim am Rhein, Germany. This initial venture laid the foundation for what would become one of the world's largest pharmaceutical companies.

Rise to Success

Mathias Boehringer's rise is tied to the continuing success of Boehringer Ingelheim. The company has grown from a small factory to a global enterprise with a presence in 130 markets and over 54,500 employees. The company's growth is attributed to its focus on innovation, particularly in human and animal health. The family's commitment to maintaining the company's private status has allowed for a long-term focus on research and development.

Key Business Strategies

Boehringer Ingelheim's strategy centers on research and development, with significant investments in new therapies. In 2024, the company invested approximately €6.2 billion (approximately $6.7 billion) in R&D. Key therapeutic areas include cardiovascular, renal, metabolic, oncology, and respiratory diseases. The company also leverages partnerships and collaborations to expand its product pipeline. Furthermore, the family's long-term vision has enabled them to prioritize innovation over short-term financial gains.

Philanthropy

Information about Mathias Boehringer's specific philanthropic activities is not readily available in the search results. However, the Boehringer Ingelheim group is known for its commitment to improving the health of humans and animals, supporting research, and engaging in sustainable development.

Career Timeline

2024

Revenue

Boehringer Ingelheim generated revenue of EUR 26.8 billion (approximately $29 billion).

2017

Business Swap with Sanofi

Boehringer Ingelheim and Sanofi signed a business swap. Boehringer Ingelheim acquired Merial, the Animal Health subsidiary of Sanofi.

1885

Foundation of Boehringer Ingelheim

Albert Boehringer founded a small tartaric acid factory in Ingelheim am Rhein, Germany, which became the cornerstone of the family's pharmaceutical enterprise.

Philanthropic Impact

Category$XB

REAL initiative

REAL description

Key Business Ventures & Holdings

CompanyStakeValue
Boehringer Ingelheim——

Net Worth History

In-Depth Analysis

Early Life

Mathias Boehringer's early life details are not widely publicized, but his roots are firmly planted in the pharmaceutical legacy of the Boehringer family. The family's history dates back to 1885 when Albert Boehringer founded a small factory in Ingelheim am Rhein, Germany. This initial venture laid the foundation for what would become one of the world's largest pharmaceutical companies.

Rise to Success

Mathias Boehringer's rise is tied to the continuing success of Boehringer Ingelheim. The company has grown from a small factory to a global enterprise with a presence in 130 markets and over 54,500 employees. The company's growth is attributed to its focus on innovation, particularly in human and animal health. The family's commitment to maintaining the company's private status has allowed for a long-term focus on research and development.

Key Business Strategies

Boehringer Ingelheim's strategy centers on research and development, with significant investments in new therapies. In 2024, the company invested approximately €6.2 billion (approximately $6.7 billion) in R&D. Key therapeutic areas include cardiovascular, renal, metabolic, oncology, and respiratory diseases. The company also leverages partnerships and collaborations to expand its product pipeline. Furthermore, the family's long-term vision has enabled them to prioritize innovation over short-term financial gains.

Philanthropy

Information about Mathias Boehringer's specific philanthropic activities is not readily available in the search results. However, the Boehringer Ingelheim group is known for its commitment to improving the health of humans and animals, supporting research, and engaging in sustainable development.

Data Sources & Methodology

Figures for Mathias Boehringer are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom